adomeglivant

a glucagon receptor antagonist

Also Known As:

(+)-adomeglivant; (+-)-adomeglivant; (-)-adomeglivant; 3-(4-((1R)-1-((4'-tert-butyl-2,6-dimethylbiphenyl-4-yl)oxy)-4,4,4-trifluorobutyl)benzamido)propanoic acid; 3-(4-((1S)-1-((4'-tert-butyl-2,6-dimethylbiphenyl-4-yl)oxy)-4,4,4-trifluorobutyl)benzamido)propanoic acid; 3-(4-1-((4'-tert-butyl-2,6-dimethylbiphenyl-4-yl)oxy)-4,4,4-trifluorobutyl)benzamido)propanoic acid; LY-2409021; LY2409021; adomeglivant, (+)-; adomeglivant, (+-)-

Networked: 11 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        adomeglivant: 11

Experts

1.	Garhyan, Parag: 5 articles (11/2017 - 07/2016)
2.	Hardy, Thomas A: 5 articles (11/2017 - 07/2016)
3.	Kazda, Christof M: 4 articles (01/2017 - 07/2016)
4.	Deeg, Mark A: 3 articles (01/2017 - 07/2016)
5.	Ding, Ying: 3 articles (01/2017 - 07/2016)
6.	Fu, Haoda: 3 articles (01/2017 - 07/2016)
7.	Kelly, Ronan P: 3 articles (01/2017 - 07/2016)
8.	Landschulz, William H: 3 articles (01/2017 - 07/2016)
9.	Lewin, Andrew J: 3 articles (01/2017 - 07/2016)
10.	Lim, Chay Ngee: 3 articles (01/2017 - 07/2016)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 04/01/2015 - "LY2409021 was administered in dose-escalation studies to healthy subjects (n = 23) and patients with type 2 diabetes (n = 9) as single doses (Study 1) and daily to patients with type 2 diabetes (n = 47) for 28 days (Study 2). " 01/01/2017 - "These effects may limit the clinical utility of LY2409021 as a chronic treatment for type 2 diabetes." 01/01/2017 - "To assess the effect of LY2409021 on systolic blood pressure (SBP) in patients with type 2 diabetes. " 01/01/2017 - "Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. " 11/01/2016 - "Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. "
2.	Hypoglycemia (Reactive Hypoglycemia) 07/01/2016 - "The incidence of hypoglycemia in the LY2409021 groups was not statistically different from placebo. "
3.	Body Weight (Weight, Body) 11/01/2017 - "LY2409021 was also associated with significant increases in systolic blood pressure vs sitagliptin (4.9 mm Hg; P = .030) and vs placebo (4.3 mm Hg; P = .029), as well as significant increases in body weight and total cholesterol. "

Related Drugs and Biologics

1.	Glucagon Receptors (Glucagon Receptor)
2.	Glucagon (Glukagon)
3.	Glucose (Dextrose)
4.	empagliflozin
5.	Incretins
6.	Cholesterol
7.	Blood Glucose (Blood Sugar)
8.	Sitagliptin Phosphate (Januvia)